H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $30 from $48 and keeps a Buy rating on the shares. The firm dropped the stock’s valuation multiples to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: